Haleon consensus picture firms, shares in focus after recall and M&A interest

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:33.

Haleon (GB00BMX86B70) sits in the consumer healthcare segment of the FTSE indices in London with a tightening analyst consensus around its shares. Recent commentary highlights mid?term operating profit growth in the high single digits and an average price target above the current quotation, according to MarketScreener.

What recent notes highlight

In a June analyst compilation, Haleon is described as projecting mid?term operating profit growth in the high single?digit range, consistent with its positioning in oral health, pain relief and vitamins products. The same MarketScreener consensus shows a last closing price of about 3484 pence and a mean target near 4136 pence, implying roughly 19 percent upside versus that level.

AlphaValue initiated coverage on Haleon in October 2023 with an "ADD" recommendation and a target of 402 pence per share, framing the group as a major player in global consumer healthcare. The research note underscores Haleon’s spin?off history from GSK in 2022 and its diversified portfolio spanning brands such as Sensodyne, Voltaren, Advil, Panadol and Centrum, which underpin expectations for steady cash flows.

How the consensus stands today

Across the current consensus snapshot, the compiled houses cluster around price targets in the low?to?mid 400 pence region, with MarketScreener’s mid?point at 4136 pence for Haleon. That sits above the recent trading band and reflects analysts’ view of a robust consumer health franchise with exposure to oral care, pain relief and respiratory categories in developed and emerging markets.

Rating distribution in the same overview leans toward positive stances, with several brokers on Buy or Add and a smaller portion on Hold, according to MarketScreener’s listing. The implied upside from the consensus target is supported by Haleon’s guidance for high single?digit operating profit growth and by its scale advantages in global brands, which research notes see as competitive strengths against peers like Johnson & Johnson’s Kenvue and Sanofi’s consumer health operations.

The business behind the stock

Haleon’s revenue base comes from a portfolio of consumer health brands such as Sensodyne in oral care, Voltaren in pain relief, Advil and Panadol in analgesics, and Centrum in vitamins and supplements. The company operates across categories including oral health, pain relief, respiratory care and vitamins/minerals/supplements, with global reach following its carve?out from GSK in 2022.

Where the shares trade

The Haleon shares (GB00BMX86B70) trade on the London Stock Exchange under the ticker HLN, with the latest available price data showing the stock quoted in pence sterling in the mid?300s as of the most recent MarketScreener update.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data and assessments are based on sources cited in the article and may change over time.